Deepa Sarvaiya

1 week ago | seekingalpha.com | Deepa Sarvaiya

Ocugen press release (NASDAQ:OCGN): Q1 GAAP EPS of -$0.05 beats by $0.01. Revenue of $1.48M (+46.5% Y/Y). The Company’s cash and restricted cash totaled $38.1 million as of March 31, 2025, compared to $58.8 million as of December 31, 2024. The Company had 292.0 million shares of common stock outstanding as of March 31, 2025. The Company expects its cash and restricted cash runway into the first quarter of 2026.

1 week ago | seekingalpha.com | Deepa Sarvaiya

Neoleukin Therapeutics press release (NASDAQ:NGNE): Q1 GAAP EPS of -$1.08 misses by $0.02. Cash, cash equivalents and short-term investments as of March 31, 2025 were $292.6 million and are expected to provide runway into the second half of 2027, which would allow for the

1 week ago | seekingalpha.com | Deepa Sarvaiya

Soligenix press release (NASDAQ:SNGX): Q1 GAAP EPS of -$1.06 misses by $0.39. Soligenix reported no revenue for the quarter ended March 31, 2025, compared to $0.1 million for the prior quarter ended March 31, 2024. The decrease was primarily related to a decrease in revenue associated with the zero-margin grant for the HyBryte™ IIS.

1 week ago | seekingalpha.com | Deepa Sarvaiya

Plains GP Holdings Non-GAAP EPS of $0.42 misses by $0.06, revenue of $12.01B misses by $980M

1 week ago | seekingalpha.com | Deepa Sarvaiya

ANI Pharmaceuticals Non-GAAP EPS of $1.70 beats by $0.32, revenue of $197.12M beats by $16.43M